CO7010825A2 - Conjugados de hidromorfona con ácido benzoico, derivados de ácido benzoico y ácido heteroarilcarboxílico, profármacos, métodos de preparación y uso de los mismos - Google Patents

Conjugados de hidromorfona con ácido benzoico, derivados de ácido benzoico y ácido heteroarilcarboxílico, profármacos, métodos de preparación y uso de los mismos

Info

Publication number
CO7010825A2
CO7010825A2 CO14089601A CO14089601A CO7010825A2 CO 7010825 A2 CO7010825 A2 CO 7010825A2 CO 14089601 A CO14089601 A CO 14089601A CO 14089601 A CO14089601 A CO 14089601A CO 7010825 A2 CO7010825 A2 CO 7010825A2
Authority
CO
Colombia
Prior art keywords
benzoic acid
acid
prodrugs
derivatives
preparation
Prior art date
Application number
CO14089601A
Other languages
English (en)
Spanish (es)
Inventor
Travis Mickle
Sven Guenther
Guochen Chi
Jaroslaw Kanski
Andrea K Martin
Bindu Bera
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of CO7010825A2 publication Critical patent/CO7010825A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CO14089601A 2011-10-26 2014-04-28 Conjugados de hidromorfona con ácido benzoico, derivados de ácido benzoico y ácido heteroarilcarboxílico, profármacos, métodos de preparación y uso de los mismos CO7010825A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551600P 2011-10-26 2011-10-26
US201261657201P 2012-06-08 2012-06-08

Publications (1)

Publication Number Publication Date
CO7010825A2 true CO7010825A2 (es) 2014-07-31

Family

ID=48168468

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14089601A CO7010825A2 (es) 2011-10-26 2014-04-28 Conjugados de hidromorfona con ácido benzoico, derivados de ácido benzoico y ácido heteroarilcarboxílico, profármacos, métodos de preparación y uso de los mismos

Country Status (20)

Country Link
US (6) US8816083B2 (enExample)
EP (1) EP2771002A4 (enExample)
JP (1) JP5769889B2 (enExample)
KR (1) KR101589846B1 (enExample)
CN (2) CN104136031B (enExample)
AR (1) AR088551A1 (enExample)
AU (1) AU2012328837B2 (enExample)
BR (1) BR112014010099A8 (enExample)
CA (1) CA2856608C (enExample)
CL (1) CL2014000995A1 (enExample)
CO (1) CO7010825A2 (enExample)
HK (2) HK1197191A1 (enExample)
IL (1) IL231822A0 (enExample)
IN (1) IN2014DN03009A (enExample)
MX (1) MX362857B (enExample)
PH (1) PH12014500791A1 (enExample)
RU (1) RU2573388C2 (enExample)
SG (1) SG11201401856VA (enExample)
WO (1) WO2013063204A1 (enExample)
ZA (1) ZA201402339B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
IN2014DN03009A (enExample) 2011-10-26 2015-05-08 Kempharm Inc
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
GB201417529D0 (en) 2014-10-03 2014-11-19 Isis Innovation Beta lactamase inhibitors
MX2017006520A (es) 2014-11-25 2017-08-09 Kempharm Inc * Acido benzoico, derivados de acido benzoico y conjugados de oxicodona de acido heteroaril carboxilico.
CA2969221C (en) 2014-12-02 2021-01-12 Travis Mickle Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US9987269B2 (en) 2015-04-27 2018-06-05 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US10226456B2 (en) 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
EP3210596A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
EP3231420A1 (en) * 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210630A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
US20200038383A1 (en) * 2016-10-14 2020-02-06 Kempharm, Inc. Immediate-release abuse deterrent compositions or medicaments for treating pain, add, adhd and other syndromes or disorders
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2021097532A1 (en) * 2019-11-22 2021-05-27 Deakin University Organic corrosion inhibitors
WO2021097531A1 (en) * 2019-11-22 2021-05-27 Deakin University Polyionic corrosion inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5952499A (en) 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
DE19602968A1 (de) * 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
NZ529661A (en) * 2001-06-05 2006-03-31 Control Delivery Systems Sustained-release analgesic compounds
US6740641B2 (en) * 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
MXPA05009757A (es) 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
EA008864B1 (ru) 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
US7661226B2 (en) * 2005-01-11 2010-02-16 Larson Manufacturing Company Installation method for a storm door
US20100144645A1 (en) * 2006-04-14 2010-06-10 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse
SG172633A1 (en) 2006-05-26 2011-07-28 Pharmacofore Inc Controlled release of phenolic opioids
EP2078269A4 (en) 2006-10-31 2011-02-23 Rebit Inc AUTOMATIC MASKING SYSTEM OF DATA AND FILE DIRECTORY STRUCTURES RECORDED ON A COMPUTER MEMORY
WO2008101202A1 (en) * 2007-02-16 2008-08-21 Pharmacofore, Inc. N-17-alkylated prodrugs of opioids
WO2009092073A2 (en) 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
CA2756397A1 (en) 2009-04-02 2010-10-07 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
CA2765836C (en) * 2009-07-02 2014-10-07 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
UA102916C2 (uk) * 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
WO2011008636A1 (en) * 2009-07-15 2011-01-20 Mallinckrodt Inc. 3-oxy-hydromorphone derivatives
PL2453895T3 (pl) 2009-07-16 2018-10-31 Mallinckrodt Llc (+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne
JP2013503862A (ja) 2009-09-08 2013-02-04 シグネーチャー セラピューティクス,インク. 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
WO2012008984A1 (en) 2010-07-16 2012-01-19 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
IN2014DN03009A (enExample) 2011-10-26 2015-05-08 Kempharm Inc

Also Published As

Publication number Publication date
CA2856608C (en) 2017-05-16
CA2856608A1 (en) 2013-05-02
BR112014010099A8 (pt) 2018-01-16
KR101589846B1 (ko) 2016-01-28
US8816083B2 (en) 2014-08-26
EP2771002A1 (en) 2014-09-03
MX2014004691A (es) 2014-07-09
SG11201401856VA (en) 2014-05-29
AU2012328837B2 (en) 2015-07-09
RU2014121065A (ru) 2015-12-10
RU2573388C2 (ru) 2016-01-20
US10064956B2 (en) 2018-09-04
JP5769889B2 (ja) 2015-08-26
US20140330021A1 (en) 2014-11-06
US20180339056A1 (en) 2018-11-29
MX362857B (es) 2019-02-20
AR088551A1 (es) 2014-06-18
IN2014DN03009A (enExample) 2015-05-08
US10441661B2 (en) 2019-10-15
CN104136031A (zh) 2014-11-05
ZA201402339B (en) 2015-07-29
IL231822A0 (en) 2014-05-28
US9566343B2 (en) 2017-02-14
KR20140089520A (ko) 2014-07-15
BR112014010099A2 (pt) 2017-06-27
US20130150395A1 (en) 2013-06-13
JP2014532651A (ja) 2014-12-08
US10258696B2 (en) 2019-04-16
US20180064820A1 (en) 2018-03-08
CN104136031B (zh) 2016-05-04
US20190192670A1 (en) 2019-06-27
WO2013063204A1 (en) 2013-05-02
US9849185B2 (en) 2017-12-26
NZ623106A (en) 2015-06-26
US20170143839A1 (en) 2017-05-25
CL2014000995A1 (es) 2014-07-25
PH12014500791A1 (en) 2022-12-02
AU2012328837A1 (en) 2014-05-01
HK1223279A1 (zh) 2017-07-28
EP2771002A4 (en) 2015-08-12
CN105749294A (zh) 2016-07-13
HK1197191A1 (en) 2015-01-09

Similar Documents

Publication Publication Date Title
CO6801742A2 (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
SMT201600157B (it) Composti di carbammoilpiridone policiclici e loro uso farmaceutico
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
HRP20170961T1 (hr) Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata
DK2387989T3 (da) Langtidsvirkende formuleringer med insuliner
CO6801741A2 (es) Derivados c4-monometil triterpenoides y sus métodos de uso
ES2897565T8 (es) Lípidos catiónicos de amina y uso de los mismos
CO6910164A2 (es) Anticuerpos a pcsk9 y usos de los mismos
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
IL252379A0 (en) Method of applying edge offset
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
BR112012021065A2 (pt) artigo de uso descartável
BR112013007506A2 (pt) piridinonas/pirazinonas - métodos de criação e de uso
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
BR112012022746A2 (pt) uso de amissulprida como anti-emético
BR112014014763A8 (pt) novos conjugados de anticorpo-medicamento (adcs) e uso dos mesmos
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
IL235734B (en) Process for the preparation of treprostinil and derivatives thereof
CO6930362A2 (es) Compuesto heterocíclico y su uso
DK3050972T3 (da) Fremgangsmåder til fremstilling af eicosapentaensyre i thraustochytrider
BR112014006482A2 (pt) uso de derivados de isossorbida para produção de preparações cosméticas
PL2678035T3 (pl) Pochodne fenalen-1-onu, sposób ich wytwarzania i zastosowanie
SG11201401856VA (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
CO7020907A2 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
SMT201600223B (it) Composti eterociclici e loro uso come modulatori di tirosin chinasi di tipo iii